Bristol Myers Squibb (CELG-RI) Operating Income (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Operating Income of $360.0 million for Q2 2026, up 122.51% year-over-year from $161.8 million in Q2 2025, and up 297.8% quarter-over-quarter from -$182.0 million in Q1 2026.
Bristol Myers Squibb (CELG-RI) Operating Income (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Operating Income for 18 consecutive years, with $360.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Operating Income rose 122.51% year-over-year to $360.0 million; the TTM figure through Jun 2026 stood at -$2.8 billion (up 63.45% YoY), while the FY2025 annual figure was -$4.6 billion, up 79.38% from the prior year.
- Operating Income advanced to $360.0 million in Q2 2026 per CELG-RI's latest filing, from -$182.0 million in the prior quarter.
- Across five years, Operating Income topped out at $360.0 million in Q2 2026 and bottomed at -$14.4 billion in Q1 2024.
- Historically, Operating Income has averaged -$1.7 billion across 5 years, with a median of -$773.0 million in 2022.
- Annual changes were most pronounced in 2023 — Operating Income surged 126.02% — and 2024, when it tumbled 7182.35%.
- Bristol Myers Squibb's Operating Income stood at -$734.0 million in 2022, then tumbled by 45.91% to -$1.1 billion in 2023, then slumped by 332.96% to -$4.6 billion in 2024, then soared by 43.35% to -$2.6 billion in 2025, then jumped by 113.7% to $360.0 million in 2026.
- Business Quant data shows CELG-RI's Operating Income at $360.0 million in Q2 2026, -$182.0 million in Q1 2026, and -$2.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 7.14 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 6.43 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -584.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 4.75 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 3.16 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 3.51 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.39 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 4.27 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 645.35 Mn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 360.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 360.00 Mn |
| Mar 31, 2026 | -182.00 Mn |
| Dec 31, 2025 | -2.63 Bn |
| Sep 30, 2025 | -321.00 Mn |
| Jun 30, 2025 | -1.60 Bn |
| Mar 31, 2025 | -62.00 Mn |
| Dec 31, 2024 | -4.64 Bn |
| Sep 30, 2024 | -1.28 Bn |
| Jun 30, 2024 | -1.98 Bn |
| Mar 31, 2024 | -14.45 Bn |
| Dec 31, 2023 | -1.07 Bn |
| Sep 30, 2023 | -369.00 Mn |
| Jun 30, 2023 | -1.02 Bn |
| Mar 31, 2023 | 204.00 Mn |
| Dec 31, 2022 | -734.00 Mn |
| Sep 30, 2022 | -144.00 Mn |
| Jun 30, 2022 | -762.00 Mn |
| Mar 31, 2022 | -784.00 Mn |
| Dec 31, 2021 | -498.00 Mn |
| Sep 30, 2021 | -134.00 Mn |